Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Targeted serum miRNA (TSmiR) test for diagnosis and follow‐up of (testicular) germ cell cancer patients: A proof of principle

Open access
Gillis, Ad J.M., Rijlaarsdam, Martin A., Eini, Ronak, Dorssers, Lambert C.J., Biermann, Katharina, Murray, Matthew J., Nicholson, James C., Coleman, Nicholas, Dieckmann, Klaus-Peter, Belge, Gazanfer, Bullerdiek, Jörn, Xu, Tom, Bernard, Nathalie, Looijenga, Leendert H.J.·2013·Molecular Oncology

Abstract

Germ cell cancers (GCC) are the most frequent malignancy in young Caucasian males. GCC can consist of seminomas (SE) and non‐seminomas (malignant NS: embryonal carcinoma (EC), yolk sac tumor (YS), choriocarcinoma (CH) and teratoma (TE)). Current serum‐markers used for diagnosis and follow‐up (AFP, hCG) are predominantly related to YS and CH and marker positivity can vary during disease. Therefore, stable markers consistently identifying more GCC components, specifically the stem cell components SE and EC, are of interest. Expression of the embryonic stem cell miR‐371‐3 and miR‐302/367 clusters in SE/EC/YS suggest possible application of these micro‐RNAs as GCC tumor‐markers. The TSmiR protocol constitutes a complete, quality‐controlled pipeline for the detection of miRs in serum, based on magnetic bead‐based purification and qPCR quantification. As a proof of principle, TSmiR was applied to five independent serum sample series including 80 GCCs, 47 controls, 11 matched pre/post orchidectomy samples and 12 no‐GCC testicular masses. GCC serum samples showed a consistent, significant (p < 0.0064) increase of miR‐371/372/373/367 levels. Analogous, serum levels returned to baseline after orchidectomy (stage‐I disease). Moreover, there was a trend toward higher miR levels in patients with metastasis. These results imply suitability for diagnosis and follow‐up. TSmiR showed an overall sensitivity of 98%, clearly outperforming the traditional serum markers AFP/hCG (36%/57%, sensitivityAFP = 3%/45%; sensitivityhCG = 62%/66%, SE/NS). TSmiR misclassified one tumor as a control. Serum AFP/hCG and TSmiR combined identified all T samples correctly. In conclusion, TSmiR constitutes a highly sensitive and reproducible serum test for GCC patients, suitable to be prospectively tested for diagnostic and follow‐up purposes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2013.08.002

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 159

Metadata

Authors
Gillis, A. J. M., Rijlaarsdam, M. A., Eini, R., Dorssers, L. C. J., Biermann, K., Murray, M. J., Nicholson, J. C., Coleman, N., Dieckmann, K.-P., Belge, G., Bullerdiek, J., Xu, T., Bernard, N., & Looijenga, L. H. J.
Venue
Molecular Oncology
Publisher
Wiley
Published
2013-08-20
Volume
7
Issue
6
Pages
1083-1092
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2057950056
Cited by
159
References
1
FWCI
14.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted serum miRNA (TSmiR) test for diagnosis and follow‐up of (testicular) germ cell cancer patients: A proof of principle. https://app.cochat.ai/papers/10.1016/j.molonc.2013.08.002
The paper
Gillis, A. J. M., Rijlaarsdam, M. A., Eini, R., Dorssers, L. C. J., Biermann, K., Murray, M. J., Nicholson, J. C., Coleman, N., Dieckmann, K.-P., Belge, G., Bullerdiek, J., Xu, T., Bernard, N., & Looijenga, L. H. J. (2013). Targeted serum miRNA (TSmiR) test for diagnosis and follow‐up of (testicular) germ cell cancer patients: A proof of principle. Molecular Oncology. https://doi.org/10.1016/j.molonc.2013.08.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.